T-Therapeutics

T-Therapeutics: Develops bispecific TCR-CD3 T cell engagers for cancer and autoimmune diseases. BioTech · Series A · Cambridge, United Kingdom. Rated 69/100…

Develops bispecific TCR-CD3 T cell engagers for cancer and autoimmune diseases.

Preliminary profile · public data only

Startup24 listed T-Therapeutics from public information on the company's own website; its founders have not claimed or verified the profile yet. The rating below is preliminary, based on public data only, and is an opinion — not investment advice. Founders can claim the profile, and anyone can report an error or request removal, on this page.

At a glance

• Category: BioTech (T-cell receptor therapeutics)
• Stage: Series A
• Location: Cambridge, United Kingdom

Startup24 rating: 69/100

T-Therapeutics is a credible Series A UK biotech pursuing large oncology and autoimmune opportunities with a differentiated TCR-CD3 platform and reported $91 million in financing.

About the rating

Every startup on Startup24 is scored on the same six criteria — team, market, product, advantages, risk and reputation — with the reasoning written out. Founders list for free; investors subscribe to see the full analysis.

• How the score is calculated
• Browse the catalogue

Startup24 (startup-24.com) rates startups on real, verified data: founders list for free, investors subscribe to find them first. Operated by DOTOVO OÜ, Tallinn, Estonia.